Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent
Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs
Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS® net product revenue
Continued disciplined financial execution with positive cash flow and GAAP operating loss of ($9.0) million and non-GAAP operating income of $22.9 million for the third quarter 2026
Updates to 2026 guidance range include raising lower end of total net product revenue by $50.0 million, driven by strong PMO performance, and lowering higher end of expense by $25.0 million, reflecting operating discipline
Growing evidence base across ambulatory population reinforces ELEVIDYS benefit- risk profile, with new clinical, biomarker and real-world data supporting durability of benefit, robust dystrophin expression and approaches to liver safety risk mitigation
CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Nov. 5, 2026 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026.
“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities,” said Michael Severino, M.D., chief executive officer, Sarepta. “This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve. We are already preparing both programs for potential late-stage development with the intent of moving efficiently if the results support advancement. We have work to do, and I want us to be measured by execution, but I believe Sarepta has the commercial foundation, pipeline opportunities and financial strength to deliver meaningful long-term value.” Corporate Highlights: DM1 and FSHD programs advancing toward MAD data in fourth quarter of 2026 and preparing for late-stage development: Multiple ascending dose data from SRP-1003 and SRP-1001 are expected in the fourth quarter of 2026, providing important insights including DMPK knockdown and splicing correction in DM1 and DUX4 knockdown in FSHD. Sarepta is actively preparing for Phase 3 development in both programs, including beginning
manufacturing of clinical supply. The Company is preparing for both accelerated and traditional approval potential pathways, with the ultimate regulatory strategy to be informed by the data and discussions with FDA.
SRP-1003 demonstrates robust nuclear DMPK knockdown in DM1: New preclinical data presented at the 2026 Oligonucleotide Therapeutics Society Annual Meeting demonstrated that SRP-1003 reduced pathogenic DMPK mRNA in both the nucleus and cytoplasm in a dose-dependent manner, achieving comparable knockdown in each compartment. Nuclear target engagement was supported by three independent methodologies, with correction of MBNL-dependent mis-splicing providing functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus.
Financial strength supports late-stage DM1 and FSHD execution: Delivered another quarter of non-GAAP operating profit and positive cash flow, ending with approximately $998.7 million in cash, cash equivalents, restricted cash and investments. Our balance-sheet strength and commercial cash flows are expected to provide the resources to fund these programs through late-stage development while maintaining disciplined capital allocation.
2026 Guidance: Company expects ELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter, consistent with previous guidance and subject to normal variability associated with one-time gene therapy. The Company expects the PMO franchise to remain strong and is updating its full-year guidance ranges, raising the low end of total net product revenue guidance by $50.0 million to a range of $1.25 billion to $1.3 billion. The Company also narrows its full-year combined non-GAAP R&D and SG&A expenses, lowering the high end of expense guidance by $25.0 million to a range of $800 million to $825 million.
Growing evidence base reinforces the ELEVIDYS benefit-risk profile: At the 2026 World Muscle Society Annual Congress, Company presented ELEVIDYS data in ambulatory patients ages 8 to 12 at the time of treatment demonstrating durable and clinically meaningful benefit across the North Star Ambulatory Assessment and timed function measures over two years compared with a well-matched external control group. Company also presented data in patients treated at ages 2 and 3 demonstrating robust ELEVIDYS-dystrophin expression and sarcolemmal localization 12 weeks after infusion. At the Annual Neuromuscular Study Group Scientific Meeting, initial results from the Phase 4 ENDURE study provided preliminary real-world data evaluating approaches to liver safety risk mitigation.
The event will be webcast live under the investor relations section of Sarepta's website athttps://investorrelations.sarepta.com/events-presentationsand following the event a replay will be archived there for one year. This event can be accessed usingthis link. 2
Total revenueswere $381.4 million for the three months ended September 30, 2026, as compared to $399.4 million for the same period of 2025, a decrease of $18.0 million. This primarily reflects a lower volume of ELEVIDYS sales due to the continued impact of our updated label that only includes the ambulatory patient population for treatment. The decrease is partially offset by an increase of $31.4 million in contract manufacturing revenues associated with increased commercial ELEVIDYS supply delivered to Roche.
Total revenues were $1,513.4 million for the nine months ended September 30, 2026, as compared to $1,755.3 million for the same period of 2025, a decrease of $241.9 million. This primarily reflects a lower volume of ELEVIDYS sales due to our updated label that only includes the ambulatory patient population for treatment. The decrease is partially offset by an increase of $189.5 million in collaboration revenues related to the $365.0 million of collaboration revenue recognized related to Roche's declined option for certain program rights and the milestone recognized under the Roche collaboration agreement for the first commercial dosing of ELEVIDYS in Japan during the nine months ended September 30, 2026, as compared to $175.5 million of collaboration revenue in 2025 related to Roche’s expiration of an option to acquire a certain program and the Japan Approval Milestone. Furthermore, contract manufacturing revenues increased $72.5 million associated with increased commercial ELEVIDYS supply delivered to Roche.
Cost of sales (excluding amortization of in-license rights)were $188.5 million for the three months ended September 30, 2026, as compared to $150.8 million for the same period of 2025, an increase of $37.7 million. Cost of sales (excluding amortization of in-license rights) were $446.7 million for the nine months ended September 30, 2026, as compared to $440.9 million for the same period of 2025, an increase of $5.8 million. The increases in both periods primarily reflect a take-or-pay charge of $62.0 million related to non-cancelable manufacturing obligations with Catalent, Inc. ("Catalent") for certain inventories that we elected not to manufacture. Additionally, there was an increase in cost of sales related to products sold to Roche, primarily related to increased volume of ELEVIDYS shipments as well as write-offs of certain batches of products not meeting quality specifications under the Roche collaboration agreement. The increases in both periods were partially offset by a lower volume of ELEVIDYS sales in the United States and corresponding royalty payments.
Research and development expenseswere $82.5 millionfor the three months ended September 30, 2026, as compared to $218.9 million for the same period of 2025, a decrease of $136.4 million. The decrease primarily reflects a $100.0 million milestone payment made to Arrowhead Pharmaceutical, Inc. ("Arrowhead") during the three months ended September 30, 2025, triggered by Arrowhead's achievement of the first of two predetermined enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 study for the DM1 program, with no similar activity during the same period of 2026. In addition, there were decreases in manufacturing and clinical expenses primarily due to our decision to reprioritize our pipeline and developmental priorities announced in July 2025, partially offset by an increase in compensation and other personnel expenses due to the reversal of previously recognized 4 expense related to certain incentive compensationour restructuring plan announced in July 2025 (the "Restructuring"). For the three months ended September 30, 2026, non-GAAP research and development expenses were $71.6 million, as compared to $206.5 million for the same period of 2025, a decrease of $134.9 million.
Research and development expenses were $327.8 million for the nine months ended September 30, 2026, as compared to $1,196.7 million for the same period of 2025, a decrease of approximately $868.9 million. The decrease primarily reflects the recognition of up-front and collaboration license fees of $583.6 million associated with the licensing, collaboration and stock purchase agreement with Arrowhead as well as the $100.0 million milestone payment made to Arrowhead during the nine months ended September 30, 2025, with no similar activity for the same period of 2026. In addition, there was a decrease in manufacturing and clinical expenses primarily due to our decision to reprioritize our pipeline and developmental priorities announced in July 2025, as well as a decrease in compensation, other personnel, and stock-based compensation expenses, all as a result of the Restructuring. This decrease was partially offset by the $50.0 million annual collaboration license fee incurred and paid to Arrowhead during the nine months ended September 30, 2026. For the nine months ended September 30, 2026, non-GAAP research and development expenses were $285.8 million, as compared to $1,137.4 million for the same period of 2025, a decrease of $851.6 million.
Selling, general and administrative expenseswere $118.6 million for the three months ended September 30, 2026, as compared to $91.9 million for the same period of 2025, an increase of $26.7 million. The increase primarily reflects the reversal of previously recognized expense related to certain stock compensation awards and incentive compensation accruals in connection with the Restructuring during the three months ended September 30, 2025, with no similar activity during the same period of 2026. For the three months ended September 30, 2026, non-GAAP selling, general and administrative expenses were $97.6 million, as compared to $77.1 million for the same period of 2025, an increase of $20.5 million.
Selling, general and administrative expenses were $335.2 million for the nine months ended September 30, 2026, as compared to $363.4 million for the same period of 2025, a decrease of $28.2 million. The decrease primarily reflects a decrease in compensation, other personnel, and stock-based compensation expenses, all as a result of the Restructuring, as well as a decrease in professional services used related to ELEVIDYS commercialization efforts. For the nine months ended September 30, 2026, non-GAAP selling, general and administrative expenses were $271.7 million, as compared to $297.6 million for the same period of 2025, a decrease of $25.9 million.
Litigation settlement chargewas $39.0 million for the nine months ended September 30, 2026, with no similar activity for the same period of 2025. We recorded a litigation settlement charge of $39.0 million in the second quarter of 2026 related to a settlement agreement that was executed in September 2026 between Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, REGENXBIO, INC, the Trustees of the University of Pennsylvania and Catalent regarding the resolution of certain patent infringement litigations. 5 Restructuring chargeswere $40.5 million for the three and nine months ended September 30, 2025, with no similar activity for the same periods of 2026.
Other (expense) income, netfor the three months ended September 30, 2026 and 2025 was approximately $(16.7) million and $35.0 million, respectively. Other expense, net for the nine months ended September 30, 2026 and 2025 was approximately $47.0 million and $10.1 million, respectively. The change primarily reflects a decrease in our strategic investments as a result of the sale of our investment in Arrowhead in August 2025, partially offset by an increase in interest expense due to our 2030 Notes carrying a higher interest rate than our 2027 Notes during the three and nine months ended September 30, 2026.
Gain on debt extinguishmentwas $3.8 million for the three and nine months ended September 30, 2025, with no similar activity for the same periods of 2026. This gain was the result of a partial refinancing of the 2027 Notes where we exchanged $700.0 million in aggregate principal amount of 2027 Notes for $602.0 million in aggregate principal amount of 2030 Notes and made cash payments of $127.3 million, including $4.0 million of accrued interest of the 2027 Notes and 5.9 million shares of our common stock with a fair market value of approximately $104.9 million, net of issuance costs of $2.4 million.
Income tax expensefor the three and nine months ended September 30, 2026, was approximately $2.7 million and $18.1 million, respectively. Income tax (benefit) expense for the three and nine months ended September 30, 2025, was $(14.1) million and $6.6 million, respectively. Income tax expense for all periods presented primarily relates to state income taxes as a result of taxable profits in certain states requiring the capitalization of research and development costs and states which have suspended or limited the utilization of net operating loss carryforwards.
In addition to the GAAP financial measures set forth in this press release, we have included the following non-GAAP measurements:
Non-GAAP net (loss) income is defined by us as GAAP net (loss) income excluding interest expense/income, net, depreciation and amortization expense, stock-based compensation expense, restructuring charges, other items, and the estimated income tax impact of each pre-tax non-GAAP adjustment.
Non-GAAP earnings per share is defined by us as non-GAAP net income, as defined previously, divided by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding, adjusted for the inclusion of additional shares under both the treasury stock method and the “if-converted” method, if applicable and not anti-dilutive. Non-GAAP net loss per share is defined by us as non-GAAP net loss, as defined above, divided by the weighted- average number of shares of common stock outstanding as the inclusion of dilutive common stock equivalents outstanding is anti-dilutive.
Non-GAAP operating income (loss) is defined by us as GAAP operating (loss) income excluding depreciation and amortization expense, stock-based compensation expense, restructuring charges and litigation settlement charges. 6 Non-GAAP research and development expenses are defined by us as GAAP research and development expenses excluding depreciation and amortization expense and stock-based compensation expense.
Non-GAAP selling, general and administrative expenses are defined by us as GAAP selling, general and administrative expenses excluding depreciation expense and stock-based compensation expense.
Non-GAAP effective tax rate is defined by us as the GAAP effective tax rate excluding the impact of our GAAP to non-GAAP adjustments.
The following components are used to adjust our GAAP financial measures into the previously defined non-GAAP measurements:
Interest, depreciation and amortization - Interest expense/income, net amounts can vary substantially from period to period due to changes in cash and debt balances and interest rates driven by market conditions outside of our operations. Depreciation expense can vary substantially from period to period as the purchases of property and equipment may vary significantly from period to period and without any direct correlation to our operating performance. Amortization expense primarily associated with patent costs are amortized over a period of several years after acquisition or patent application or renewal.
Stock-based compensation expenses - Stock-based compensation expenses represent non-cash charges related to equity awards we have granted. Although these are recurring charges to operations, we believe the measurement of these amounts can vary substantially from period to period and depend significantly on factors that are not a direct consequence of operating performance that is within our control. Therefore, we believe that excluding these charges facilitates comparisons of our operational performance in different periods.
Restructuring charges do not have a direct correlation to future business operations, nor do the resulting charges recorded reflect the performance of our ongoing operations for the period in which such charges are recorded. In addition, restructuring charges are not considered to be normal operating expenses due to the variability of amounts and lack of predictability as to occurrence and/or timing.
Other items - We evaluate other items of expense and income on an individual basis. We take into consideration quantitative and qualitative characteristics of each item, including (a) nature, (b) whether the items relate to our ongoing business operations, and (c) whether we expect the items to continue or occur on a regular basis. These other items include the loss (gain) on strategic investments, the impairment of strategic investments, litigation settlement charges, and gain on debt extinguishment and may include other items that fit the above characteristics in the future. We exclude from our non-GAAP results:
The loss (gain) on strategic investments as the results of such gains and losses are not representative of our normal business operations, which accordingly would make it difficult to compare our results to peer companies that also provide non-GAAP disclosures.
The impairment of strategic investments as such charges are not indicative of the performance of our core operations, which accordingly would make it difficult to compare our results to peer companies that also provide non-GAAP disclosures.
Litigation settlement charge as such charges are considered to be an infrequent event as it is associated with a distinct, non-recurring litigation matter and is not indicative 7 of the performance of our core operations nor representative of our normal business operations, which accordingly would make it difficult to compare our results to peer companies that also provide non-GAAP disclosures.
The gain on debt extinguishment is considered to be an infrequent event as it is associated with a distinct financing decision and is not indicative of the performance of our core operations, which accordingly would make it difficult to compare our results to peer companies that also provide non-GAAP disclosures.
We use these non-GAAP measures as key performance measures for the purpose of evaluating operational performance and cash requirements internally. We also believe these non-GAAP measures increase comparability of period-to-period results and are useful to investors as they provide a similar basis for evaluating our performance as is applied by management. These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of our financial results in accordance with GAAP. Use of the terms non-GAAP research and development expenses, non-GAAP selling, general and administrative expenses, non-GAAP operating income (loss), non-GAAP net income (loss), and non- GAAP diluted earnings (loss) per share may differ from similar measures reported by other companies, which may limit comparability, and are not based on any comprehensive set of accounting rules or principles. All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”
EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion, or “skipping”, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of theDMDgene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
EXONDYS 51 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Hypersensitivity reactions, including bronchospasm, chest pain, cough, tachycardia, and urticaria have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.
Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended. 8 The most common adverse reactions from observational clinical studies (N=163) seen in greater than 10% of patients were headache, cough, rash, and vomiting.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at 1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for EXONDYS 51 (eteplirsen).
VYONDYS 53 (golodirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.
VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of theDMDgene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
VYONDYS 53 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
CONTRAINDICATIONS:VYONDYS 53 is contraindicated in patients with a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53. Anaphylaxis has occurred in patients receiving VYONDYS 53.
Hypersensitivity Reactions:Hypersensitivity reactions, including anaphylaxis, rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion, interrupting, or discontinuing the VYONDYS 53 therapy and monitor until the condition resolves. VYONDYS 53 is contraindicated in patients with a history of a serious hypersensitivity reaction to golodirsen or to any of the inactive ingredients in VYONDYS 53. 9 Kidney Toxicity:Kidney toxicity was observed in animals who received golodirsen. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to- creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
ADVERSE REACTIONS:Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).
Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at 1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for VYONDYS 53 (golodirsen).
AMONDYS 45 (casimersen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. 10 AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of theDMDgene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
AMONDYS 45 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.
Important Safety Information for AMONDYS 45 CONTRAINDICATION: AMONDYS 45 is contraindicated in patients with a known serious hypersensitivity to casimersen or any of the inactive ingredients in AMONDYS 45. Instances of hypersensitivity including angioedema and anaphylaxis have occurred. WARNINGS AND PRECAUTIONS
Hypersensitivity:Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. If a hypersensitivity reaction occurs, institute appropriate medical treatment, and consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 infusion and monitor until the condition resolves. AMONDYS 45 is contraindicated in patients with known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45.
Kidney Toxicity: Kidney toxicity was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with AMONDYS 45, kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Adverse Reactions:Adverse reactions occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%). 11 Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light- headedness.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at 1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for AMONDYS 45 (casimersen). About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
ELEVIDYS is indicated for the treatment of ambulatory patients 4 years of age and older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in theDMDgene.
Preexisting liver impairment (defined as gamma-glutamyl transferase [GGT] > 2 x upper limit of normal or total bilirubin > the upper limit of normal not due to Gilbert’s syndrome) or active hepatic viral infection due to the high risk of acute serious liver injury and acute liver failure.
Recent vaccination (within 4 weeks of treatment) due to immunogenicity and potential safety concerns.
Acute serious liver injury, including life-threatening and fatal acute liver failure, has occurred. Patients with preexisting liver impairment may be at higher risk.
Prior to infusion, assess liver function by clinical examination and laboratory testing. Administer systemic corticosteroids before and after ELEVIDYS infusion. Continue to monitor liver function weekly for the first 3 months after infusion and continue until results are unremarkable.
Instruct patients to maintain proximity to an appropriate healthcare facility, as determined by the healthcare provider, for at least 2 months following ELEVIDYS infusion.
Obtain prompt consultation with a specialist (e.g., gastroenterologist or hepatologist) if acute serious liver injury or impending acute liver failure is suspected. 12 CONTRAINDICATION:ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9,including a deletion of any portion or the entirety of these exons,in theDMDgene.
Acute serious liver injury marked by elevations of liver enzymes (e.g., GGT, ALT) and total bilirubin and acute liver failure has occurred with ELEVIDYS. Onset of the liver injury typically begins within 8 weeks of ELEVIDYS administration. In non-ambulatory patients treated with ELEVIDYS, acute liver failure with fatal outcome has occurred in the clinical and post-marketing settings. Life-threatening mesenteric vein thrombosis, complicated by bowel ischemia and necrosis, and portal hypertension have been reported following acute liver injury associated with ELEVIDYS in a non-ambulatory patient.
Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury or acute liver failure. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled.
Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated.
Increased susceptibility to serious infections may occur due to concomitant administration of corticosteroid regimen and additional immunosuppressants, and ELEVIDYS. Serious respiratory infections, including with fatal outcomes, have occurred in patients taking immunosuppressant corticosteroids required for ELEVIDYS administration.
Monitor patients for signs and symptoms of infection before and after ELEVIDYS administration and treat appropriately.
Administer immunizations according to best clinical practices and immunization guidelines prior to initiation of the corticosteroid regimen required before ELEVIDYS infusion.
Acute, serious, life-threatening myocarditis and troponin-I elevations have been observed within 24 hours to more than 1 year following ELEVIDYS infusion.
If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes.
Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated, until results return to near baseline levels or stabilize.
More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath.
Advise patients to contact a physician immediately if they experience cardiac symptoms.
Infusion-related Reactions 13 Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate.
ELEVIDYS should be administered in a setting where treatment for infusion- related reactions is immediately available.
Immune-mediated myositis, including serious and life-threatening events, has occurred approximately 1 month following ELEVIDYS infusion. Signs and symptoms include severe muscle weakness, including dysphagia, dyspnea, dysphonia, and hypophonia.
Severe to life-threatening immune-mediated myositis has been reported in patients with deletions including portions of exons 1-17 and/or exons 59-71 of the DMD gene.
Regardless of genetic mutation, advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, dysphonia, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment based on patient’s clinical presentation and medical history if these symptoms occur.
In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies.
Perform baseline testing for the presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration.
ELEVIDYS administration is not recommended in patients with elevated anti- AAVrh74 total binding antibody titers ≥1:400.
The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased.
Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).
Please see the full Prescribing Information for ELEVIDYS, including Boxed Warning and Medication Guide.
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are 14 building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.comor follow us onLinkedIn, X, Instagram and Facebook.
In order to provide Sarepta’s investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance, projections and guidance, business plans, market opportunities and potential growth, priorities and research and development programs and technologies; the potential benefits of our technologies and scientific approaches, including our siRNA programs; the timing of our ongoing and planned clinical trials; and our expected plans and milestones, including upcoming data readouts for DM1 and FSHDby the end of 2026. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, the results of future research may not be consistent with past positive results, or may fail to meet regulatory approval requirements for the safety and efficacy of our products; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; we may observe adverse reactions in our clinical trials or in patients who receive our approved products; our products may not be widely adopted by patients, payors or healthcare providers, which would adversely impact our business; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; certain programs may never advance in the clinic or may be discontinued for a number of reasons, including regulators imposing a clinical hold and us suspending or terminating clinical research or trials; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. 15
Sarepta Therapeutic… Inc. Condensed Consolidated Balance Sheets (unaudited, in thousands, except share and per share amounts) Assets As of As of Current September 30, December 31, assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 472,760 $ 801,282 equivalents Short-term 406,016 138,368 investments Accounts receivable, 369,178 398,233 net Inventory 876,118 914,744 Manufacturi… deposits and 62,206 113,455 prepaids Other current 86,611 171,856 assets Total current 2,272,889 2,537,938 assets Property and equipment, 319,288 345,125 net Right of use 117,709 125,495 assets Non-current 200,579 184,543 inventory Non-current 108,815 1,048 investments Other non-current 146,786 155,554 assets Total assets $ 3,166,066 $ 3,349,703 Liabilities and Stockholder… Equity Current liabilities: Accounts $ 45,704 $ 280,841 payable Accrued 321,764 359,659 expenses Deferred revenue, 104,887 443,397 current portion Current portion of 157,971 — long-term debt Other current 26,027 11,393 liabilities Total current 656,353 1,095,290 liabilities Long-term 699,393 828,974 debt Lease liabilities, net of 195,663 199,378 current portion Deferred revenue, net 83,910 83,910 of current portion Other non-current 1,894 1,529 liabilities Total 1,637,213 2,209,081 liabilities Stockholder… equity: Preferred stock, $0.0001 par value, 3,333,333 — — shares authorized; none issued and outstanding Common stock, $0.0001 par value, 198,000,000 shares authorized; 107,888,367 and 107,232,725 issued and outstanding, 11 11 respectivel… at September 30, 2026 and 105,615,096 and 104,964,220 issued and outstanding, respectivel… at December 31, 2025 Treasury stock, at cost, 655,642 and 650,876 shares at (25,013 ) (25,263 ) September 30, 2026 and December 31, 2025, respectively Additional paid-in 6,134,817 6,042,586 capital Accumulated other comprehensi… (1,586 ) 272 (loss) income, net of tax Accumulated (4,579,376 ) (4,876,984 ) deficit Total stockholder… 1,528,853 1,140,622 equity Total liabilities and $ 3,166,066 $ 3,349,703 stockholder… equity
Full text with the tables
Exhibit 99.1
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent
Corporate Developments
Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD
expected by year end; Company is actively preparing for Phase 3 development in
both programs
Net product revenues for the third quarter 2026 totaled approximately $323.8
million, consisting of approximately $240.3 million of PMO net product revenues
and $83.5 million of ELEVIDYS® net product revenue
Continued disciplined financial execution with positive cash flow and GAAP
operating loss of ($9.0) million and non-GAAP operating income of $22.9 million
for the third quarter 2026
Updates to 2026 guidance range include raising lower end of total net product
revenue by $50.0 million, driven by strong PMO performance, and lowering higher
end of expense by $25.0 million, reflecting operating discipline
Growing evidence base across ambulatory population reinforces ELEVIDYS benefit-
risk profile, with new clinical, biomarker and real-world data supporting
durability of benefit, robust dystrophin expression and approaches to liver
safety risk mitigation
CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Nov. 5, 2026 -- Sarepta Therapeutics,
Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,
today reported financial results for the third quarter of 2026.
“After my first 90 days at Sarepta, I believe the fundamental strengths that
attracted me to the company remain firmly intact: a durable Duchenne franchise,
a promising pipeline with the potential to deliver differentiated medicines, and
the financial strength to invest in our highest-value opportunities,” said
Michael Severino, M.D., chief executive officer, Sarepta. “This quarter, we saw
continued strength in our commercial execution. Our upcoming DM1 and FSHD
datasets are important opportunities to demonstrate the depth of knockdown and
downstream biological effects we believe our platform can achieve. We are
already preparing both programs for potential late-stage development with the
intent of moving efficiently if the results support advancement. We have work to
do, and I want us to be measured by execution, but I believe Sarepta has the
commercial foundation, pipeline opportunities and financial strength to deliver
meaningful long-term value.”
Corporate Highlights:
DM1 and FSHD programs advancing toward MAD data in fourth quarter of 2026 and
preparing for late-stage development: Multiple ascending dose data from SRP-1003
and SRP-1001 are expected in the fourth quarter of 2026, providing important
insights including DMPK knockdown and splicing correction in DM1 and DUX4
knockdown in FSHD. Sarepta is actively preparing for Phase 3 development in both
programs, including beginning
manufacturing of clinical supply. The Company is preparing for both accelerated
and traditional approval potential pathways, with the ultimate regulatory
strategy to be informed by the data and discussions with FDA.
SRP-1003 demonstrates robust nuclear DMPK knockdown in DM1: New preclinical data
presented at the 2026 Oligonucleotide Therapeutics Society Annual Meeting
demonstrated that SRP-1003 reduced pathogenic DMPK mRNA in both the nucleus and
cytoplasm in a dose-dependent manner, achieving comparable knockdown in each
compartment. Nuclear target engagement was supported by three independent
methodologies, with correction of MBNL-dependent mis-splicing providing
functional evidence that SRP-1003 is degrading disease-causing RNA within the
nucleus.
Financial strength supports late-stage DM1 and FSHD execution: Delivered another
quarter of non-GAAP operating profit and positive cash flow, ending with
approximately $998.7 million in cash, cash equivalents, restricted cash and
investments. Our balance-sheet strength and commercial cash flows are expected
to provide the resources to fund these programs through late-stage development
while maintaining disciplined capital allocation.
2026 Guidance: Company expects ELEVIDYS net product revenue in the fourth
quarter to trend in line with the third quarter, consistent with previous
guidance and subject to normal variability associated with one-time gene
therapy. The Company expects the PMO franchise to remain strong and is updating
its full-year guidance ranges, raising the low end of total net product revenue
guidance by $50.0 million to a range of $1.25 billion to $1.3 billion. The
Company also narrows its full-year combined non-GAAP R&D and SG&A expenses,
lowering the high end of expense guidance by $25.0 million to a range of $800
million to $825 million.
Growing evidence base reinforces the ELEVIDYS benefit-risk profile: At the 2026
World Muscle Society Annual Congress, Company presented ELEVIDYS data in
ambulatory patients ages 8 to 12 at the time of treatment demonstrating durable
and clinically meaningful benefit across the North Star Ambulatory Assessment
and timed function measures over two years compared with a well-matched external
control group. Company also presented data in patients treated at ages 2 and 3
demonstrating robust ELEVIDYS-dystrophin expression and sarcolemmal localization
12 weeks after infusion. At the Annual Neuromuscular Study Group Scientific
Meeting, initial results from the Phase 4 ENDURE study provided preliminary
real-world data evaluating approaches to liver safety risk mitigation.
Conference Call
The event will be webcast live under the investor relations section of Sarepta's
website athttps://investorrelations.sarepta.com/events-presentationsand
following the event a replay will be archived there for one year. This event can
be accessed usingthis link.
2
For
the
Three
Q3 Mont…
2026 Ended
Fin… Sept… QTD
Hig… 30 2026 2025 Change
──────────────────────────────────────────────────────────────────────────────
-in
mill…
exce…
for $ %
per
share
amou…
Tot… $ 381.4 $ 399.4 $ (18.0 ) (5 )%
rev…
Ope…
(lo…
inc…
GAAP $ (9.0 ) $ (103.4 ) $ 94.4 (91 )%
Non… $ 22.9 $ (35.7 ) $ 58.6 *
Net
(lo…
inc…
GAA… $ (28.5 ) $ (50.6 ) $ 22.1 (44 )%
Non… $ 15.6 $ (12.9 ) $ 28.5 *
Dil…
(lo…
ear…
per
sha…
GAA… $ (0.27 ) $ (0.50 ) $ 0.23 (46 )%
Non… $ 0.13 $ (0.13 ) $ 0.26 *
For
the
Nine
Mont…
Ended
Sept…
30
2026 2025 YTD
Chan…
-in
mill…
exce…
for $ %
per
share
amou…
Tot… $ 1,51… $ 1,755… $ (241.9 ) (14 )%
rev…
Ope…
inc…
(lo…
GAAP $ 362.7 $ (288.2 ) $ 650.9 *
Non… $ 507.1 $ (122.5 ) $ 629.6 *
Net
inc…
(lo…
GAA… $ 297.6 $ (301.2 ) $ 598.8 *
Non… $ 479.6 $ (130.2 ) $ 609.8 *
Dil…
ear…
(lo…
per
sha…
GAA… $ 2.78 $ (3.06 ) $ 5.84 *
Non… $ 3.91 $ (1.32 ) $ 5.23 *
1
For
an
exp…
of
our
use
of
non…
fin…
mea…
ple…
ref…
to
the
“Use
of
Non…
Fin…
Mea…
sec…
lat…
in
this
pre…
rel…
and
for
a
rec…
of
each
non…
fin…
mea…
from
the
most
com…
GAAP
mea…
see
the
tab…
at
the
end
of
this
pre…
rel…
2
GAAP
net
loss
and
dil…
loss
per
sha…
for
the
thr…
and
nine
mon…
end…
Sep…
30,
2025
have
been
rev…
to
ref…
the
cor…
of
an
imm…
err…
ass…
with
the
acc…
for
the
Aug…
2025
Exc…
as
well
as
the
ado…
of
ASU
202…
Ple…
ref…
to
the
Com…
Ann…
Rep…
on
Form
10-K
for
the
year
end…
Dec…
31,
2025
for
add…
inf…
*Not
mea…
As of
September 30, As of
2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
-in millions
Cash, cash
equivalents, $ 998.7 $ 953.8
restricted cash
and investments
3
Revenues
Total revenueswere $381.4 million for the three months ended September 30, 2026,
as compared to $399.4 million for the same period of 2025, a decrease of $18.0
million. This primarily reflects a lower volume of ELEVIDYS sales due to the
continued impact of our updated label that only includes the ambulatory patient
population for treatment. The decrease is partially offset by an increase of
$31.4 million in contract manufacturing revenues associated with increased
commercial ELEVIDYS supply delivered to Roche.
Total revenues were $1,513.4 million for the nine months ended September 30,
2026, as compared to $1,755.3 million for the same period of 2025, a decrease of
$241.9 million. This primarily reflects a lower volume of ELEVIDYS sales due to
our updated label that only includes the ambulatory patient population for
treatment. The decrease is partially offset by an increase of $189.5 million in
collaboration revenues related to the $365.0 million of collaboration revenue
recognized related to Roche's declined option for certain program rights and the
milestone recognized under the Roche collaboration agreement for the first
commercial dosing of ELEVIDYS in Japan during the nine months ended September
30, 2026, as compared to $175.5 million of collaboration revenue in 2025 related
to Roche’s expiration of an option to acquire a certain program and the Japan
Approval Milestone. Furthermore, contract manufacturing revenues increased $72.5
million associated with increased commercial ELEVIDYS supply delivered to Roche.
Cost of sales (excluding amortization of in-licensed rights)
Cost of sales (excluding amortization of in-license rights)were $188.5 million
for the three months ended September 30, 2026, as compared to $150.8 million for
the same period of 2025, an increase of $37.7 million. Cost of sales (excluding
amortization of in-license rights) were $446.7 million for the nine months ended
September 30, 2026, as compared to $440.9 million for the same period of 2025,
an increase of $5.8 million. The increases in both periods primarily reflect a
take-or-pay charge of $62.0 million related to non-cancelable manufacturing
obligations with Catalent, Inc. ("Catalent") for certain inventories that we
elected not to manufacture. Additionally, there was an increase in cost of sales
related to products sold to Roche, primarily related to increased volume of
ELEVIDYS shipments as well as write-offs of certain batches of products not
meeting quality specifications under the Roche collaboration agreement. The
increases in both periods were partially offset by a lower volume of ELEVIDYS
sales in the United States and corresponding royalty payments.
Operating expenses and others
Research and development expenseswere $82.5 millionfor the three months ended
September 30, 2026, as compared to $218.9 million for the same period of 2025, a
decrease of $136.4 million. The decrease primarily reflects a $100.0 million
milestone payment made to Arrowhead Pharmaceutical, Inc. ("Arrowhead") during
the three months ended September 30, 2025, triggered by Arrowhead's achievement
of the first of two predetermined enrollment targets and subsequent
authorization to dose escalate in a Phase 1/2 study for the DM1 program, with no
similar activity during the same period of 2026. In addition, there were
decreases in manufacturing and clinical expenses primarily due to our decision
to reprioritize our pipeline and developmental priorities announced in July
2025, partially offset by an increase in compensation and other personnel
expenses due to the reversal of previously recognized
4
expense related to certain incentive compensationour restructuring plan
announced in July 2025 (the "Restructuring"). For the three months ended
September 30, 2026, non-GAAP research and development expenses were $71.6
million, as compared to $206.5 million for the same period of 2025, a decrease
of $134.9 million.
Research and development expenses were $327.8 million for the nine months ended
September 30, 2026, as compared to $1,196.7 million for the same period of 2025,
a decrease of approximately $868.9 million. The decrease primarily reflects the
recognition of up-front and collaboration license fees of $583.6 million
associated with the licensing, collaboration and stock purchase agreement with
Arrowhead as well as the $100.0 million milestone payment made to Arrowhead
during the nine months ended September 30, 2025, with no similar activity for
the same period of 2026. In addition, there was a decrease in manufacturing and
clinical expenses primarily due to our decision to reprioritize our pipeline and
developmental priorities announced in July 2025, as well as a decrease in
compensation, other personnel, and stock-based compensation expenses, all as a
result of the Restructuring. This decrease was partially offset by the $50.0
million annual collaboration license fee incurred and paid to Arrowhead during
the nine months ended September 30, 2026. For the nine months ended September
30, 2026, non-GAAP research and development expenses were $285.8 million, as
compared to $1,137.4 million for the same period of 2025, a decrease of $851.6
million.
Selling, general and administrative expenseswere $118.6 million for the three
months ended September 30, 2026, as compared to $91.9 million for the same
period of 2025, an increase of $26.7 million. The increase primarily reflects
the reversal of previously recognized expense related to certain stock
compensation awards and incentive compensation accruals in connection with the
Restructuring during the three months ended September 30, 2025, with no similar
activity during the same period of 2026. For the three months ended September
30, 2026, non-GAAP selling, general and administrative expenses were $97.6
million, as compared to $77.1 million for the same period of 2025, an increase
of $20.5 million.
Selling, general and administrative expenses were $335.2 million for the nine
months ended September 30, 2026, as compared to $363.4 million for the same
period of 2025, a decrease of $28.2 million. The decrease primarily reflects a
decrease in compensation, other personnel, and stock-based compensation
expenses, all as a result of the Restructuring, as well as a decrease in
professional services used related to ELEVIDYS commercialization efforts. For
the nine months ended September 30, 2026, non-GAAP selling, general and
administrative expenses were $271.7 million, as compared to $297.6 million for
the same period of 2025, a decrease of $25.9 million.
Litigation settlement chargewas $39.0 million for the nine months ended
September 30, 2026, with no similar activity for the same period of 2025. We
recorded a litigation settlement charge of $39.0 million in the second quarter
of 2026 related to a settlement agreement that was executed in September 2026
between Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, REGENXBIO,
INC, the Trustees of the University of Pennsylvania and Catalent regarding the
resolution of certain patent infringement litigations.
5
Restructuring chargeswere $40.5 million for the three and nine months ended
September 30, 2025, with no similar activity for the same periods of 2026.
Other (expense) income, netfor the three months ended September 30, 2026 and
2025 was approximately $(16.7) million and $35.0 million, respectively. Other
expense, net for the nine months ended September 30, 2026 and 2025 was
approximately $47.0 million and $10.1 million, respectively. The change
primarily reflects a decrease in our strategic investments as a result of the
sale of our investment in Arrowhead in August 2025, partially offset by an
increase in interest expense due to our 2030 Notes carrying a higher interest
rate than our 2027 Notes during the three and nine months ended September 30,
2026.
Gain on debt extinguishmentwas $3.8 million for the three and nine months ended
September 30, 2025, with no similar activity for the same periods of 2026. This
gain was the result of a partial refinancing of the 2027 Notes where we
exchanged $700.0 million in aggregate principal amount of 2027 Notes for $602.0
million in aggregate principal amount of 2030 Notes and made cash payments of
$127.3 million, including $4.0 million of accrued interest of the 2027 Notes and
5.9 million shares of our common stock with a fair market value of approximately
$104.9 million, net of issuance costs of $2.4 million.
Income tax expensefor the three and nine months ended September 30, 2026, was
approximately $2.7 million and $18.1 million, respectively. Income tax (benefit)
expense for the three and nine months ended September 30, 2025, was $(14.1)
million and $6.6 million, respectively. Income tax expense for all periods
presented primarily relates to state income taxes as a result of taxable profits
in certain states requiring the capitalization of research and development costs
and states which have suspended or limited the utilization of net operating loss
carryforwards.
Use of Non-GAAP Financial Measures
In addition to the GAAP financial measures set forth in this press release, we
have included the following non-GAAP measurements:
Non-GAAP net (loss) income is defined by us as GAAP net (loss) income excluding
interest expense/income, net, depreciation and amortization expense, stock-based
compensation expense, restructuring charges, other items, and the estimated
income tax impact of each pre-tax non-GAAP adjustment.
Non-GAAP earnings per share is defined by us as non-GAAP net income, as defined
previously, divided by the weighted-average number of shares of common stock and
dilutive common stock equivalents outstanding, adjusted for the inclusion of
additional shares under both the treasury stock method and the “if-converted”
method, if applicable and not anti-dilutive. Non-GAAP net loss per share is
defined by us as non-GAAP net loss, as defined above, divided by the weighted-
average number of shares of common stock outstanding as the inclusion of
dilutive common stock equivalents outstanding is anti-dilutive.
Non-GAAP operating income (loss) is defined by us as GAAP operating (loss)
income excluding depreciation and amortization expense, stock-based compensation
expense, restructuring charges and litigation settlement charges.
6
Non-GAAP research and development expenses are defined by us as GAAP research
and development expenses excluding depreciation and amortization expense and
stock-based compensation expense.
Non-GAAP selling, general and administrative expenses are defined by us as GAAP
selling, general and administrative expenses excluding depreciation expense and
stock-based compensation expense.
Non-GAAP effective tax rate is defined by us as the GAAP effective tax rate
excluding the impact of our GAAP to non-GAAP adjustments.
The following components are used to adjust our GAAP financial measures into the
previously defined non-GAAP measurements:
Interest, depreciation and amortization - Interest expense/income, net amounts
can vary substantially from period to period due to changes in cash and debt
balances and interest rates driven by market conditions outside of our
operations. Depreciation expense can vary substantially from period to period as
the purchases of property and equipment may vary significantly from period to
period and without any direct correlation to our operating performance.
Amortization expense primarily associated with patent costs are amortized over a
period of several years after acquisition or patent application or renewal.
Stock-based compensation expenses - Stock-based compensation expenses represent
non-cash charges related to equity awards we have granted. Although these are
recurring charges to operations, we believe the measurement of these amounts can
vary substantially from period to period and depend significantly on factors
that are not a direct consequence of operating performance that is within our
control. Therefore, we believe that excluding these charges facilitates
comparisons of our operational performance in different periods.
Restructuring charges do not have a direct correlation to future business
operations, nor do the resulting charges recorded reflect the performance of our
ongoing operations for the period in which such charges are recorded. In
addition, restructuring charges are not considered to be normal operating
expenses due to the variability of amounts and lack of predictability as to
occurrence and/or timing.
Other items - We evaluate other items of expense and income on an individual
basis. We take into consideration quantitative and qualitative characteristics
of each item, including (a) nature, (b) whether the items relate to our ongoing
business operations, and (c) whether we expect the items to continue or occur on
a regular basis. These other items include the loss (gain) on strategic
investments, the impairment of strategic investments, litigation settlement
charges, and gain on debt extinguishment and may include other items that fit
the above characteristics in the future. We exclude from our non-GAAP results:
The loss (gain) on strategic investments as the results of such gains and losses
are not representative of our normal business operations, which accordingly
would make it difficult to compare our results to peer companies that also
provide non-GAAP disclosures.
The impairment of strategic investments as such charges are not indicative of
the performance of our core operations, which accordingly would make it
difficult to compare our results to peer companies that also provide non-GAAP
disclosures.
Litigation settlement charge as such charges are considered to be an infrequent
event as it is associated with a distinct, non-recurring litigation matter and
is not indicative
7
of the performance of our core operations nor representative of our normal
business operations, which accordingly would make it difficult to compare our
results to peer companies that also provide non-GAAP disclosures.
The gain on debt extinguishment is considered to be an infrequent event as it is
associated with a distinct financing decision and is not indicative of the
performance of our core operations, which accordingly would make it difficult to
compare our results to peer companies that also provide non-GAAP disclosures.
We use these non-GAAP measures as key performance measures for the purpose of
evaluating operational performance and cash requirements internally. We also
believe these non-GAAP measures increase comparability of period-to-period
results and are useful to investors as they provide a similar basis for
evaluating our performance as is applied by management. These non-GAAP measures
are not intended to be considered in isolation or to replace the presentation of
our financial results in accordance with GAAP. Use of the terms non-GAAP
research and development expenses, non-GAAP selling, general and administrative
expenses, non-GAAP operating income (loss), non-GAAP net income (loss), and non-
GAAP diluted earnings (loss) per share may differ from similar measures reported
by other companies, which may limit comparability, and are not based on any
comprehensive set of accounting rules or principles. All relevant non-GAAP
measures are reconciled from their respective GAAP measures in the attached
table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial
Measures.”
About EXONDYS 51
EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer
(PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin
pre-mRNA, resulting in exclusion, or “skipping”, of this exon during mRNA
processing in patients with genetic mutations that are amenable to exon 51
skipping. Exon skipping is intended to allow for production of an internally
truncated dystrophin protein.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD)
in patients who have a confirmed mutation of theDMDgene that is amenable to exon
51 skipping. This indication is approved under accelerated approval based on an
increase in dystrophin in skeletal muscle observed in some patients treated with
EXONDYS 51. Continued approval for this indication may be contingent upon
verification of a clinical benefit in confirmatory trials.
EXONDYS 51 has met the full statutory standards for safety and effectiveness and
as such is not considered investigational or experimental.
Important Safety Information About EXONDYS 51
Hypersensitivity reactions, including bronchospasm, chest pain, cough,
tachycardia, and urticaria have occurred in patients who were treated with
EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical
treatment and consider slowing the infusion or interrupting the EXONDYS 51
therapy.
Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 mg or 50
mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more
than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance
disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The
most common adverse reactions were balance disorder and vomiting. Because of the
small numbers of patients, these represent crude frequencies that may not
reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing
regimen of EXONDYS 51 is not recommended.
8
The most common adverse reactions from observational clinical studies (N=163)
seen in greater than 10% of patients were headache, cough, rash, and vomiting.
Other adverse events may occur.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at
1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for
EXONDYS 51 (eteplirsen).
About VYONDYS 53
VYONDYS 53 (golodirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino
oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of
dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during
mRNA processing in patients with genetic mutations that are amenable to exon 53
skipping. Exon skipping is intended to allow for production of an internally
truncated dystrophin protein.
VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD)
in patients who have a confirmed mutation of theDMDgene that is amenable to exon
53 skipping. This indication is approved under accelerated approval based on an
increase in dystrophin production in skeletal muscle observed in patients
treated with VYONDYS 53. Continued approval for this indication may be
contingent upon verification of a clinical benefit in confirmatory trials.
VYONDYS 53 has met the full statutory standards for safety and effectiveness and
as such is not considered investigational or experimental.
Important Safety Information for VYONDYS 53
CONTRAINDICATIONS:VYONDYS 53 is contraindicated in patients with a serious
hypersensitivity reaction to golodirsen or to any of the inactive ingredients in
VYONDYS 53. Anaphylaxis has occurred in patients receiving VYONDYS 53.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions:Hypersensitivity reactions, including anaphylaxis,
rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have
occurred in VYONDYS 53-treated patients, some requiring treatment. If a
hypersensitivity reaction occurs, institute appropriate medical treatment and
consider slowing the infusion, interrupting, or discontinuing the VYONDYS 53
therapy and monitor until the condition resolves. VYONDYS 53 is contraindicated
in patients with a history of a serious hypersensitivity reaction to golodirsen
or to any of the inactive ingredients in VYONDYS 53.
9
Kidney Toxicity:Kidney toxicity was observed in animals who received golodirsen.
Although kidney toxicity was not observed in the clinical studies with VYONDYS
53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity,
including potentially fatal glomerulonephritis, has been observed after
administration of some antisense oligonucleotides. Kidney function should be
monitored in patients taking VYONDYS 53. Because of the effect of reduced
skeletal muscle mass on creatinine measurements, creatinine may not be a
reliable measure of kidney function in DMD patients. Serum cystatin C, urine
dipstick, and urine protein-to-creatinine ratio should be measured before
starting VYONDYS 53. Consider also measuring glomerular filtration rate using an
exogenous filtration marker before starting VYONDYS 53. During treatment,
monitor urine dipstick every month, and serum cystatin C and urine protein-to-
creatinine ratio every three months. Only urine expected to be free of excreted
VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the
day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48
hours after the most recent infusion, may be used. Alternatively, use a
laboratory test that does not use the reagent pyrogallol red, as this reagent
has the potential to cross react with any VYONDYS 53 that is excreted in the
urine and thus lead to a false positive result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer
to a pediatric nephrologist for further evaluation.
ADVERSE REACTIONS:Adverse reactions observed in at least 20% of treated patients
and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%),
pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis
(27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).
Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS
53-treated patients and at a greater frequency than placebo were: administration
site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion,
influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal
allergy, tachycardia, catheter site related reaction, constipation, and
fracture.
Other adverse events may occur.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at
1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for
VYONDYS 53 (golodirsen).
About AMONDYS 45
AMONDYS 45 (casimersen) uses Sarepta’s proprietary phosphorodiamidate morpholino
oligomer (PMO) chemistry and exon-skipping technology to bind to exon 45 of
dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during
mRNA processing in patients with genetic mutations that are amenable to exon 45
skipping. Exon skipping is intended to allow for production of an internally
truncated dystrophin protein.
10
AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD)
in patients who have a confirmed mutation of theDMDgene that is amenable to exon
45 skipping. This indication is approved under accelerated approval based on an
increase in dystrophin production in skeletal muscle observed in patients
treated with AMONDYS 45. Continued approval for this indication may be
contingent upon verification of a clinical benefit in confirmatory trials.
AMONDYS 45 has met the full statutory standards for safety and effectiveness and
as such is not considered investigational or experimental.
Important Safety Information for AMONDYS 45
CONTRAINDICATION: AMONDYS 45 is contraindicated in patients with a known serious
hypersensitivity to casimersen or any of the inactive ingredients in AMONDYS 45.
Instances of hypersensitivity including angioedema and anaphylaxis have
occurred.
WARNINGS AND PRECAUTIONS
Hypersensitivity:Hypersensitivity reactions, including angioedema and
anaphylaxis, have occurred in patients who were treated with AMONDYS 45. If a
hypersensitivity reaction occurs, institute appropriate medical treatment, and
consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45
infusion and monitor until the condition resolves. AMONDYS 45 is contraindicated
in patients with known serious hypersensitivity to casimersen or to any of the
inactive ingredients in AMONDYS 45.
Kidney Toxicity: Kidney toxicity was observed in animals who received
casimersen. Although kidney toxicity was not observed in the clinical studies
with AMONDYS 45, kidney toxicity, including potentially fatal
glomerulonephritis, has been observed after administration of some antisense
oligonucleotides. Kidney function should be monitored in patients taking AMONDYS
45. Because of the effect of reduced skeletal muscle mass on creatinine
measurements, creatinine may not be a reliable measure of kidney function in DMD
patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine
ratio should be measured before starting AMONDYS 45. Consider also measuring
glomerular filtration rate using an exogenous filtration marker before starting
AMONDYS 45. During treatment, monitor urine dipstick every month, and serum
cystatin C and urine protein to-creatinine ratio (UPCR) every three months. Only
urine expected to be free of excreted AMONDYS 45 should be used for monitoring
of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the
infusion, or urine obtained at least 48 hours after the most recent infusion,
may be used. Alternatively, use a laboratory test that does not use the reagent
pyrogallol red, as this reagent has the potential to cross react with any
AMONDYS 45 that is excreted in the urine and thus lead to a false positive
result for urine protein.
If a persistent increase in serum cystatin C or proteinuria is detected, refer
to a pediatric nephrologist for further evaluation.
Adverse Reactions:Adverse reactions occurring in at least 20% of patients
treated with AMONDYS 45 and at least 5% more frequently than in the placebo
group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough
(33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and
oropharyngeal pain (21%, 7%).
11
Other adverse reactions that occurred in at least 10% of patients treated with
AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear
pain, nausea, ear infection, post-traumatic pain, and dizziness and light-
headedness.
Other adverse events may occur.
To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at
1-888-SAREPTA (1-888-727-3782) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please see the full U.S. Prescribing Information for
AMONDYS 45 (casimersen).
About ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated
virus (AAV)-based gene transfer therapy for intravenous infusion designed to
address the underlying genetic cause of Duchenne muscular dystrophy – mutations
or changes in the DMD gene that result in the lack of dystrophin protein –
through the delivery of a transgene that codes for the targeted production of
ELEVIDYS micro-dystrophin in skeletal muscle.
ELEVIDYS is indicated for the treatment of ambulatory patients 4 years of age
and older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation
in theDMDgene.
Limitations of Use
ELEVIDYS is not recommended in patients with:
Preexisting liver impairment (defined as gamma-glutamyl transferase [GGT] > 2 x
upper limit of normal or total bilirubin > the upper limit of normal not due to
Gilbert’s syndrome) or active hepatic viral infection due to the high risk of
acute serious liver injury and acute liver failure.
Recent vaccination (within 4 weeks of treatment) due to immunogenicity and
potential safety concerns.
Active or recent (within 4 weeks) infections due to safety concerns.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: Acute Serious Liver Injury and Acute Liver Failure
Acute serious liver injury, including life-threatening and fatal acute liver
failure, has occurred. Patients with preexisting liver impairment may be at
higher risk.
Prior to infusion, assess liver function by clinical examination and laboratory
testing. Administer systemic corticosteroids before and after ELEVIDYS infusion.
Continue to monitor liver function weekly for the first 3 months after infusion
and continue until results are unremarkable.
Instruct patients to maintain proximity to an appropriate healthcare facility,
as determined by the healthcare provider, for at least 2 months following
ELEVIDYS infusion.
Obtain prompt consultation with a specialist (e.g., gastroenterologist or
hepatologist) if acute serious liver injury or impending acute liver failure is
suspected.
12
CONTRAINDICATION:ELEVIDYS is contraindicated in patients with any deletion in
exon 8 and/or exon 9,including a deletion of any portion or the entirety of
these exons,in theDMDgene.
WARNINGS AND PRECAUTIONS:
Acute Serious Liver Injury and Acute Liver Failure
SeeBoxed Warning.
Acute serious liver injury marked by elevations of liver enzymes (e.g., GGT,
ALT) and total bilirubin and acute liver failure has occurred with ELEVIDYS.
Onset of the liver injury typically begins within 8 weeks of ELEVIDYS
administration. In non-ambulatory patients treated with ELEVIDYS, acute liver
failure with fatal outcome has occurred in the clinical and post-marketing
settings.
Life-threatening mesenteric vein thrombosis, complicated by bowel ischemia and
necrosis, and portal hypertension have been reported following acute liver
injury associated with ELEVIDYS in a non-ambulatory patient.
Patients with preexisting liver impairment, chronic hepatic condition, or acute
liver disease (e.g., acute hepatic viral infection) may be at higher risk of
acute serious liver injury or acute liver failure. Postpone ELEVIDYS
administration in patients with acute liver disease until resolved or
controlled.
Systemic corticosteroid treatment is recommended for patients before and after
ELEVIDYS infusion. Adjust corticosteroid regimen when indicated.
Serious Infections
Increased susceptibility to serious infections may occur due to concomitant
administration of corticosteroid regimen and additional immunosuppressants, and
ELEVIDYS. Serious respiratory infections, including with fatal outcomes, have
occurred in patients taking immunosuppressant corticosteroids required for
ELEVIDYS administration.
Monitor patients for signs and symptoms of infection before and after ELEVIDYS
administration and treat appropriately.
Administer immunizations according to best clinical practices and immunization
guidelines prior to initiation of the corticosteroid regimen required before
ELEVIDYS infusion.
Avoid administration of ELEVIDYS to patients with active infections.
Myocarditis
Acute, serious, life-threatening myocarditis and troponin-I elevations have been
observed within 24 hours to more than 1 year following ELEVIDYS infusion.
If a patient experiences myocarditis, those with pre-existing left ventricle
ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes.
Monitor troponin-I before ELEVIDYS infusion and weekly for the first month
following infusion and continue monitoring if clinically indicated, until
results return to near baseline levels or stabilize.
More frequent monitoring may be warranted in the presence of cardiac symptoms,
such as chest pain or shortness of breath.
Advise patients to contact a physician immediately if they experience cardiac
symptoms.
Infusion-related Reactions
13
Infusion-related reactions, including hypersensitivity reactions and
anaphylaxis, have occurred during or up to several hours following ELEVIDYS
administration. Closely monitor patients during and for at least 3 hours after
the end of infusion. If symptoms of infusion-related reactions occur, slow or
stop the infusion and give appropriate treatment. Once symptoms resolve, the
infusion may be restarted at a lower rate.
ELEVIDYS should be administered in a setting where treatment for infusion-
related reactions is immediately available.
Discontinue infusion for anaphylaxis.
Immune-mediated Myositis
Immune-mediated myositis, including serious and life-threatening events, has
occurred approximately 1 month following ELEVIDYS infusion. Signs and symptoms
include severe muscle weakness, including dysphagia, dyspnea, dysphonia, and
hypophonia.
Severe to life-threatening immune-mediated myositis has been reported in
patients with deletions including portions of exons 1-17 and/or exons 59-71 of
the DMD gene.
Regardless of genetic mutation, advise patients to contact a physician
immediately if they experience any unexplained increased muscle pain,
tenderness, or weakness, including dysphagia, dyspnea, dysphonia, or hypophonia,
as these may be symptoms of myositis. Consider additional immunomodulatory
treatment based on patient’s clinical presentation and medical history if these
symptoms occur.
Preexisting Immunity against AAVrh74
In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede
transgene expression at desired therapeutic levels. Following treatment with
ELEVIDYS, all patients developed anti-AAVrh74 antibodies.
Perform baseline testing for the presence of anti-AAVrh74 total binding
antibodies prior to ELEVIDYS administration.
ELEVIDYS administration is not recommended in patients with elevated anti-
AAVrh74 total binding antibody titers ≥1:400.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥5%) reported in clinical studies
were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I
increased.
Report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to
Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).
Please see the full Prescribing Information for ELEVIDYS, including Boxed
Warning and Medication Guide.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare
diseases that devastate lives and cut futures short. We hold a leadership
position in Duchenne muscular dystrophy (Duchenne) and are
14
building a robust portfolio of programs across muscle, central nervous system,
and cardiac diseases. For more information, please visit www.sarepta.comor
follow us onLinkedIn, X, Instagram and Facebook.
Forward-Looking Statements
In order to provide Sarepta’s investors with an understanding of its current
results and future prospects, this press release contains statements that are
forward-looking. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,”
“intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions
are intended to identify forward-looking statements. These forward-looking
statements include statements relating to our future operations, financial
performance, projections and guidance, business plans, market opportunities and
potential growth, priorities and research and development programs and
technologies; the potential benefits of our technologies and scientific
approaches, including our siRNA programs; the timing of our ongoing and planned
clinical trials; and our expected plans and milestones, including upcoming data
readouts for DM1 and FSHDby the end of 2026.
These forward-looking statements involve risks and uncertainties, many of which
are beyond Sarepta’s control. Actual results could materially differ from those
stated or implied by these forward-looking statements as a result of such risks
and uncertainties. Known risk factors include the following: different
methodologies, assumptions and applications we use to assess particular safety
or efficacy parameters may yield different statistical results, and even if we
believe the data collected from clinical trials are positive, the results of
future research may not be consistent with past positive results, or may fail to
meet regulatory approval requirements for the safety and efficacy of our
products; success in preclinical and clinical trials, especially if based on a
small patient sample, does not ensure that later clinical trials will be
successful; our products or product candidates may be perceived as
insufficiently effective, unsafe or may result in unforeseen adverse events; we
may observe adverse reactions in our clinical trials or in patients who receive
our approved products; our products may not be widely adopted by patients,
payors or healthcare providers, which would adversely impact our business; our
products or product candidates may cause undesirable side effects that result in
significant negative consequences following any marketing approval; certain
programs may never advance in the clinic or may be discontinued for a number of
reasons, including regulators imposing a clinical hold and us suspending or
terminating clinical research or trials; if the actual number of patients
suffering from the diseases we aim to treat is smaller than estimated, our
revenue and ability to achieve profitability may be adversely affected; we may
not be able to execute on our business plans, including meeting our expected or
planned regulatory milestones and timelines, research and clinical development
plans, and bringing our product candidates to market, for various reasons, some
of which may be outside of our control, including possible limitations of
company financial and other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, and regulatory, court or agency
decisions, such as decisions by the United States Patent and Trademark Office
with respect to patents that cover our product candidates; and those risks
identified under the heading “Risk Factors” in our most recent Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as
other SEC filings made by the Company which you are encouraged to review.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For
Investors' section of our website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important information
about us.
15
16
Sar…
The…
Inc.
Con…
Con…
Sta…
of
(Lo…
Inc…
(un… For For
in the the
tho… Three Nine
exc… Mont… Mon…
per Ended End…
sha… Sept… Sep…
amo… 30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Pro… $ 323,… $ 370,… $ 982,… $ 1,4…
net
Col…
and 57,5… 29,3… 530,… 260…
oth…
Tot… 381,… 399,… 1,51… 1,7…
rev…
Cost
and
exp…
Cost
of
sal…
(ex… 188,… 150,… 446,… 440…
amo…
of
in-…
rig…
Res…
and 82,5… 218,… 327,… 1,1…
dev…
Sel…
gen… 118,… 91,8… 335,… 363…
and
adm…
Lit…
set… — — 39,0… —
cha…
Res… — 40,5… — 40,…
cha…
Amo…
of 718 677 2,126 1,9…
in-…
rig…
Tot…
cost 390,… 502,… 1,15… 2,0…
and
exp…
Ope…
(lo… (9,0… ) (103… ) 362,… (28… )
inc…
Oth…
(lo…
inc…
net:
Oth…
(ex… (16,… ) 34,9… (47,… ) (10… )
inc…
net1
Gain
on — 3,761 — 3,7…
debt
ext…
Tot…
oth…
(lo… (16,… ) 38,7… (47,… ) (6,… )
inc…
net
(Lo…
inc…
bef…
inc… (25,… ) (64,… ) 315,… (29… )
tax
exp…
(be…
Inc…
tax 2,695 (14,… ) 18,0… 6,6…
exp…
(be…
Net
(lo… $ (28,… ) $ (50,… ) $ 297,… $ (30… )
inc…
(Lo…
ear…
per
sha…
Bas… $ (0.27 ) $ (0.50 ) $ 2.82 $ (3.… )
Dil… $ (0.27 ) $ (0.50 ) $ 2.78 $ (3.… )
Wei…
ave…
num…
of
sha…
of
com…
sto…
used
in
com…
(lo…
ear…
per
sha…
Bas… 105,… 100,… 105,… 98,…
Dil… 105,… 100,… 107,… 98,…
1
Oth…
(ex…
inc…
net
and
gain
on
debt
ext…
for
the
thr…
and
nine
mon…
end…
Sep…
30,
2025
have
been
rev…
to
ref…
the
cor…
of
an
imm…
err…
ass…
with
the
acc…
for
the
Aug…
2025
Exc…
as
well
as
the
ado…
of
ASU
202…
Ple…
ref…
to
the
Com…
Ann…
Rep…
on
Form
10-K
for
the
year
end…
Dec…
31,
2025
for
add…
inf…
17
Sar…
The…
Inc.
Rec…
of
GAAP
Fin…
Mea…
to
Non…
Fin…
Mea…
(un…
in
tho…
exc…
per
sha…
amo…
For For
the the
Three Nine
Mont… Mon…
Ended End…
Sept… Sep…
30, 30,
2026 2025 2026 2025
GAAP
net $ (28,… ) $ (50,… ) $ 297,… $ (30… )
(lo…
inc…
Int…
exp… 16,0… 1,078 42,3… (8,… )
(in…
net1
Dep…
and 5,182 12,2… 24,7… 31,…
amo…
exp…
Sto…
com… 26,7… 14,9… 80,6… 93,…
exp…
Loss
(ga…
on 523 (36,… ) 2,683 17,…
str…
inv…
Res… — 40,5… — 40,…
cha…
Imp…
of — — 1,000 —
str…
inv…
Lit…
set… — — 39,0… —
cha…
Gain
on — (3,7… ) — (3,… )
debt
ext…
Inc…
tax
eff… (4,4… ) 9,477 (8,4… ) 607
of
adj…
Non…
net $ 15,6… $ (12,… ) $ 479,… $ (13… )
inc…
(lo…
GAAP
(lo…
ear…
per $ (0.27 ) $ (0.50 ) $ 2.78 $ (3.… )
sha…
-
dil…
1, 2
Add:
imp…
of
GAAP 0.40 0.37 1.13 1.74
to
Non…
adj…
Non…
ear…
(lo…
per $ 0.13 $ (0.13 ) $ 3.91 $ (1.… )
sha…
-
dil…
Wei…
ave…
num…
of
sha…
of
com…
sto…
used
in
com…
dil…
ear…
(lo…
per
sha…
GAAP 105,… 100,… 107,… 98,…
Non… 123,… 100,… 122,… 98,…
1
GAAP
net
(lo…
inc…
int…
exp…
(in…
net,
gain
on
debt
ext…
GAAP
dil…
loss
per
sha…
and
the
cor…
imp…
of
the…
GAAP
to
non…
adj…
for
the
thr…
and
nine
mon…
end…
Sep…
30,
2025
have
been
rev…
to
ref…
the
cor…
of
an
imm…
err…
ass…
with
the
acc…
for
the
Aug…
2025
Exc…
as
well
as
the
ado…
of
ASU
202…
Ple…
ref…
to
the
Com…
Ann…
Rep…
on
Form
10-K
for
the
year
end…
Dec…
31,
2025
for
add…
inf…
2
GAAP
and
non…
ear…
per
sha…
is
cal…
usi…
dil…
sha…
whe…
GAAP
and
non…
net
loss
per
sha…
is
cal…
usi…
bas…
sha…
as
all
oth…
ins…
are
ant…
3The
dif…
bet…
the
wei…
ave…
num…
of
sha…
of
com…
sto…
used
in
com…
dil…
GAAP
and
non…
ear…
per
sha…
for
the
nine
mon…
end…
Sep…
30,
2026
is a
res…
of
the
exc…
of
the
pot…
sha…
set…
of
the
2030
Con…
Not…
from
the
GAAP
ear…
per
sha…
as
the
inc…
of
such
sha…
was
ant…
18
Sa…
Th…
In…
Re…
of
GA…
Fi…
Me…
to
No…
Fi…
Me…
(u…
in
th…
ex…
per
sh…
am…
GA…
re…
and
de…
ex… For For
St… the the
co… Thr… Nine
ex… Mon… Mon…
De… End… End…
and Sep… 82,… 218… Sep… 327… 1,…
am… 30, (8,… ) (4,… ) 30, (27… ) (3… )
ex… 2026 (2,… ) 2025 (8,… ) 2026 (14… ) 2025 (2… )
──────────────────────────────────────────────────────────────────────────────
No…
re…
and $ 71,… $ 206… $ 285… $ 1,…
de…
ex…
For For
the the
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
2026 2025 2026 2025
GA…
se…
ge… $ 118… $ 91,… $ 335… $ 36…
and
ad…
ex…
St…
co… (18… ) (10… ) (53… ) (5… )
ex…
De… (2,… ) (3,… ) (10… ) (9… )
ex…
No…
se…
ge… $ 97,… $ 77,… $ 271… $ 29…
and
ad…
ex…
For For
the the
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
2026 2025 2026 2025
GA…
op… $ (9,… ) $ (10… ) $ 362… $ (2… )
(l…
in…
St…
co… 26,… 14,… 80,… 93…
ex…
De…
and 5,1… 12,… 24,… 31…
am…
ex…
Re… — 40,… — 40…
ch…
Li…
se… — — 39,… —
ch…
No…
op… $ 22,… $ (35… ) $ 507… $ (1… )
in…
(l…
For For
the the
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
2026 2025 2026 2025
To…
ef…
tax (10… ) % 21.8 % 5.7 % (2… ) %
ra…
GA…
Le…
im…
of
GA… 41.9 42.9 (0.5 ) (2… )
to
no…
ad…
To…
ef…
tax 31.4 % 64.7 % 5.2 % (4… ) %
ra…
No…
1
To…
ef…
tax
ra…
GA…
and
im…
of
GA…
to
no…
ad…
for
the
th…
and
ni…
mo…
en…
Se…
30,
20…
ha…
be…
re…
to
re…
the
co…
of
an
im…
er…
as…
wi…
the
ac…
for
the
Au…
20…
Ex…
as
we…
as
the
ad…
of
ASU
20…
Pl…
re…
to
the
Co…
An…
Re…
on
Fo…
10…
for
the
ye…
en…
De…
31,
20…
for
ad…
in…
19
Sarepta
Therapeutic…
Inc.
Condensed
Consolidated
Balance
Sheets
(unaudited,
in
thousands,
except share
and per
share
amounts)
Assets As of As of
Current September 30, December 31,
assets: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and
cash $ 472,760 $ 801,282
equivalents
Short-term 406,016 138,368
investments
Accounts
receivable, 369,178 398,233
net
Inventory 876,118 914,744
Manufacturi…
deposits and 62,206 113,455
prepaids
Other
current 86,611 171,856
assets
Total
current 2,272,889 2,537,938
assets
Property and
equipment, 319,288 345,125
net
Right of use 117,709 125,495
assets
Non-current 200,579 184,543
inventory
Non-current 108,815 1,048
investments
Other
non-current 146,786 155,554
assets
Total assets $ 3,166,066 $ 3,349,703
Liabilities
and
Stockholder…
Equity
Current
liabilities:
Accounts $ 45,704 $ 280,841
payable
Accrued 321,764 359,659
expenses
Deferred
revenue, 104,887 443,397
current
portion
Current
portion of 157,971 —
long-term
debt
Other
current 26,027 11,393
liabilities
Total
current 656,353 1,095,290
liabilities
Long-term 699,393 828,974
debt
Lease
liabilities,
net of 195,663 199,378
current
portion
Deferred
revenue, net 83,910 83,910
of current
portion
Other
non-current 1,894 1,529
liabilities
Total 1,637,213 2,209,081
liabilities
Stockholder…
equity:
Preferred
stock,
$0.0001 par
value,
3,333,333 — —
shares
authorized;
none issued
and
outstanding
Common
stock,
$0.0001 par
value,
198,000,000
shares
authorized;
107,888,367
and
107,232,725
issued and
outstanding, 11 11
respectivel…
at September
30, 2026 and
105,615,096
and
104,964,220
issued and
outstanding,
respectivel…
at December
31, 2025
Treasury
stock, at
cost,
655,642 and
650,876
shares at (25,013 ) (25,263 )
September
30, 2026 and
December 31,
2025,
respectively
Additional
paid-in 6,134,817 6,042,586
capital
Accumulated
other
comprehensi… (1,586 ) 272
(loss)
income, net
of tax
Accumulated (4,579,376 ) (4,876,984 )
deficit
Total
stockholder… 1,528,853 1,140,622
equity
Total
liabilities
and $ 3,166,066 $ 3,349,703
stockholder…
equity
20
Source: Sarepta Therapeutics, Inc.
Investor Contacts:
Ian Estepan, 617-274-4052,[email protected]
Ryan Wong, 617-800-4112,[email protected]
Tam Thornton, 617-803-3825,[email protected]
Media Contacts:
Tracy Sorrentino, 617-301-8566,[email protected]
Kara Hoeger, 617-710-3898,[email protected]
21